AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02738840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan
Study NCT04013555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: Flavored effervescent formulation
Study NCT04013555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flavored effervescent formulation designed to mimic NAC
Study NCT04013555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: Oral slurry form
Study NCT04013555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tryptophan
Description: Oral slurry form
Study NCT02707224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R208
Description: Investigational product is prescribed to all of randomized subjects
Study NCT02707224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: Investigational product is prescribed to all of randomized subjects
Study NCT02707224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Investigational product is prescribed to all of randomized subjects
Study NCT04618224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DDART Testing
Description: One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
Study NCT04618224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: wDDART Testing
Description: One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
Study NCT03361449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamingo exercise
Description: Flamingo exercise
Study NCT03361449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training with kinesthetic ability trainer
Description: training with kinesthetic ability trainer
Study NCT03889379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of albuterol
Description: Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
Study NCT03181464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 4%
Description: lidocaine solution
Study NCT03181464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline .9% injection
Study NCT01331824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
Study NCT02312336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cohort A - Room temperature coronary perfusate
Description: Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
Study NCT02312336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cohort B - Cooled coronary perfusate
Description: Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees.
Study NCT03617653 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Group A
Description: Refer to detailed study Description
Study NCT00157014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral
Study NCT00157014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Oral
Study NCT00157014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Intravenous and Oral
Study NCT00157014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Intravenous and Oral
Study NCT00157014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Intravenous
Study NCT00157014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous
Study NCT00157014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral
Study NCT00157014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral
Study NCT00616733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-0777 tablets
Description: 0.1 mg, once-weekly, for 12 weeks
Study NCT00616733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-0777 tablets
Description: 0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
Study NCT00616733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-0777 tablets
Description: 0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
Study NCT01966627 — intervention group
Intervention type: OTHER
Intervention: ogtt
Description: oral glucose tolerance test
Study NCT01966627 — intervention group
Intervention type: OTHER
Intervention: genotyping
Description: genotyping to look for risk alleles
Study NCT01966627 — intervention group
Intervention type: OTHER
Intervention: abdominal and liver magnetic resonance imaging
Description: magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
Study NCT01966627 — intervention group
Intervention type: OTHER
Intervention: stool sample
Description: stool sample taken to investigate metabolites
Study NCT01966627 — intervention group
Intervention type: OTHER
Intervention: liver biopsy
Description: liver biopsy to examine for cellular change and steatosis
Study NCT00876447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 300U
Description: Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
Study NCT01151579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levalbuterol
Description: inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
Study NCT01151579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Nebulized albuterol 2.5mg
Study NCT00288860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone monitoring
Description: Three months of biweekly telephone monitoring and support
Study NCT00288860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment-As-Usual
Description: Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
Study NCT00288860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-As-Usual
Description: Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
Study NCT03442829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet food consumption
Description: Sweet food consumption at breakfast
Study NCT03442829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-sweet food consumption
Description: Non-sweet food consumption at breakfast
Study NCT00502801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doripenem
Description: 1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
Study NCT02456649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MarginProbe
Description: Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to \< 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as \< 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
Study NCT03282149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: IL-10 transgene DNA plasmid injected into the knee synovial capsule
Study NCT04619875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: KB5
Description: KB5, a novel glycan, is a Kaleido laboratory code for KB174
Study NCT04619875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SG1
Description: SG1 is a novel glycan
Study NCT04619875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lactulose
Description: Lactulose is a synthetic dissacharide
Study NCT03553433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Anti-psoriatic drug
Study NCT03553433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
Study NCT03641209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 10mg/mL infusion solution
Description: Intravenous paracetamol solution for infusion
Study NCT03641209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half physiological saline solution as the non-active placebo solution
Study NCT00547378 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim
Study NCT00547378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
Study NCT02097758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter device closure
Description: Closure of atrial septal defect with device~* choosing device size with 3D image and the formula~* we do not use sizing balloon for choosing of the device size
Study NCT01260766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oplon Active Patch
Description: Patches are placed over acne lesion overnight. Treatment is a single treatment.
Study NCT01260766 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: same as active patch
Study NCT03924791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: In combination with dexamethasone or methylprednisolone acetate
Study NCT03924791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Acetate
Description: In combination with lidocaine
Study NCT02171104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion given on Day 0
Study NCT03924791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In combination with lidocaine
Study NCT02045212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201
Description: SC injection twice a week during 13/26 weeks
Study NCT02045212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection twice a week during 13/26 weeks
Study NCT03284008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual manoeuver + stretching
Description: Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
Study NCT03284008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
Study NCT02171104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMD Preparative Regimen
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan
Study NCT02171104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteopetrosis Only Preparative Regimen
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Thiotepa
Study NCT02171104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteopetrosis Haploidentical Only Preparative Regimen
Description: * Rituximab~* Alemtuzumab~* Busulfan~* Fludarabine
Study NCT02171104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cALD SR-A (Standard-Risk, Regimen A)
Description: N-acetylcysteine start day +1 through day +28
Study NCT02171104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cALD SR-B (Standard-Risk, Regimen B)
Description: N-acetylcysteine start day +1through day +56
Study NCT03282149 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: XT-150
Description: IL-10 transgene DNA plasmid injected into the knee synovial capsule
Study NCT04407299 — intervention group
Intervention type: BEHAVIORAL
Intervention: self-administered structured questionnaire
Description: It was designed as a self-administered questionnaire with closed questions (yes/no questions, rating scale and multiple choice questions) and some open ended questions.
Study NCT02336620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer acetate
Description: Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
Study NCT02336620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
Study NCT03163849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir , daclatasvir
Description: Tablets
Study NCT03163849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral tablets
Study NCT02744599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany
Description: Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
Study NCT01546649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP-144-SR(6M)
Study NCT01546649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP-144-SR(3M)
Study NCT03708159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS + mindfulness meditation
Description: Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
Study NCT03708159 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS + mindfulness meditation
Description: Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
Study NCT02950142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPOE with order sets for lab testing
Description: CPOE including series of recommended tests ordered per indication
Study NCT02950142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPOE without order sets for lab testing
Description: CPOE only
Study NCT01393730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Study NCT01393730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Study NCT01393730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT01920542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of dexmedetomidine on dexemedetomidine group
Study NCT01920542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: no dexmedetomidine
Description: no administration of dexmedetomidine on control group
Study NCT02790541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperbaric Oxygen Therapy
Description: 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
Study NCT02790541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
Study NCT05064774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release technique
Description: myofascial release group took myofascial release (MFR) therapy sessions twice a week for 4 weeks between 4 and 7 weeks. MFR was applied to upper trapezius, SCM, pectoralis major-minor and sternocostal fascia. muscle was replaced elongated position and pressure was applied for 60-120 second.
Study NCT05064774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.
Study NCT05064774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.
Study NCT03123783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody
Study NCT03123783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint (PD-1) blocking antibody
Study NCT03003260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD chewing gum
Study NCT03003260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04030520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POPPi behavioral intervention
Description: behavioral intervention with offer of HIV self test
Study NCT04030520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: POPPi behavioral intervention
Description: behavioral intervention
Study NCT02984852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
Study NCT02171104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cALD HR-D (High-Risk, Regimen C)
Description: N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
Study NCT02984852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI)
Description: Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
Study NCT00876447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 200U
Description: Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
Study NCT02984852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)
Description: Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
Study NCT02984852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF)
Description: Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
Study NCT01893658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: administration of a single dose together with the standard treatment
Study NCT01893658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: standard treatment
Study NCT04507477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
Study NCT02961712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: single intravenous injection of NK cells (0.9\~1\*10\^9)
Study NCT02961712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: amniotic epithelial cells
Description: single intrathecal injection of amniotic epithelial cells
Study NCT03508141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate
Description: Experimental
Study NCT03508141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Comparator
Study NCT03974113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitusiran
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous